ClearPoint Neuro (CLPT) Stock Overview
A commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CLPT Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
ClearPoint Neuro, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.14 |
| 52 Week High | US$30.10 |
| 52 Week Low | US$8.60 |
| Beta | 1.07 |
| 1 Month Change | -6.73% |
| 3 Month Change | -33.19% |
| 1 Year Change | -30.18% |
| 3 Year Change | 6.53% |
| 5 Year Change | -57.53% |
| Change since IPO | -69.53% |
Recent News & Updates
Recent updates
Regulatory Setbacks In Cell And Gene Therapy Will Eventually Reward Patient Long Term Holders
Catalysts About ClearPoint Neuro ClearPoint Neuro provides minimally invasive neurosurgery systems and tools that support drug, cell and gene therapy delivery to the brain. What are the underlying business or industry changes driving this perspective?
IRRAS Merger And Gene Therapy Ecosystem Will Transform Long Term Neurosurgical Platform Potential
Catalysts About ClearPoint Neuro ClearPoint Neuro develops and sells neurosurgical navigation, drug delivery and cranial access technologies used across preclinical research, clinical trials and hospital procedures. What are the underlying business or industry changes driving this perspective?ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 39% Cheaper Price Remains In Tune With Revenues
Nov 10
Is ClearPoint Neuro (NASDAQ:CLPT) A Risky Investment?
Nov 03ClearPoint Neuro: AMT-130 Highlights A Bright Future
Oct 02Why Investors Shouldn't Be Surprised By ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 84% Share Price Surge
Sep 25After Leaping 31% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
May 04ClearPoint Neuro: Fundamentals Continue To Strengthen
Apr 29
Cell And Gene Therapy Delivery Will Expand Global Partnerships
Strategic partnerships and global expansion aim to boost revenue and earnings through enhanced technology access and new pharma agreements.After Leaping 25% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
Feb 14After Leaping 26% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
Dec 10Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%
Sep 14Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?
Aug 16Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%
Jul 11ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 09ClearPoint Neuro: Macro-Induced Multiple Compression
Apr 25Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?
Apr 19Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report
Mar 15Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?
Jan 04Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?
Dec 06Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?
Nov 06Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?
Aug 18ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump
Apr 17Shareholder Returns
| CLPT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.7% | -1.3% | -0.6% |
| 1Y | -30.2% | -13.5% | 16.0% |
Return vs Industry: CLPT underperformed the US Medical Equipment industry which returned -13.5% over the past year.
Return vs Market: CLPT underperformed the US Market which returned 16% over the past year.
Price Volatility
| CLPT volatility | |
|---|---|
| CLPT Average Weekly Movement | 13.5% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: CLPT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CLPT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 172 | Joe Burnett | www.clearpointneuro.com |
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform.
ClearPoint Neuro, Inc. Fundamentals Summary
| CLPT fundamental statistics | |
|---|---|
| Market cap | US$269.94m |
| Earnings (TTM) | -US$25.54m |
| Revenue (TTM) | US$36.97m |
Is CLPT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLPT income statement (TTM) | |
|---|---|
| Revenue | US$36.97m |
| Cost of Revenue | US$14.28m |
| Gross Profit | US$22.69m |
| Other Expenses | US$48.23m |
| Earnings | -US$25.54m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.86 |
| Gross Margin | 61.38% |
| Net Profit Margin | -69.08% |
| Debt/Equity Ratio | 175.1% |
How did CLPT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/01 21:45 |
| End of Day Share Price | 2026/04/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ClearPoint Neuro, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Kyle Bauser | B. Riley Securities, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |